Sundrug Co.,Ltd.
Sundrug Co.,Ltd. scores highest on Anchor (79) and lowest on Nitro (38). Its PosiPenta is 60.60 out of 100, better than most similar companies.
On the Penta Grid this week, Sundrug Co.,Ltd. is Grid #20 of 140 in the Healthcare sector in Japan, and Grid #346 of 1,958 in Japan.
Compared with similar companies in the Healthcare sector in Japan.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Sundrug Co.,Ltd. | 60.60 | 57 | 67 | 38 | 62 | 79 |
| Kusuri No Aoki Holdings Co., Ltd. | 58.52 | 23 | 64 | 85 | 47 | 73 |
| Santen Pharmaceutical Co., Ltd. | 58.39 | 48 | 50 | 57 | 85 | 52 |
| Fukuda Denshi Co., Ltd. | 63.66 | 50 | 66 | 84 | 72 | 47 |
| Tsumura & Co. | 61.45 | 82 | 69 | 48 | 48 | 60 |
| Oncolys BioPharma Inc. | 33.32 | 0 | 10 | 99 | 25 | 32 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | 13.51 |
| P/B ratio | 1.45 |
EEarnings
| Trailing EPS | ₹158.59 |
| Forward EPS | ₹165.42 |
NNitro
| Price | 2142.97 |
| 52-week high | 2692.12 |
| 52-week low | 2113.43 |
| Fall from 52-week high | 20.4% |
TTorque
| Return on equity (ROE) | 11.31% |
| Debt-to-equity | 0.17 |
AAnchor
| Beta (price swings) | 0.09 |
| Market cap | ₹25,069 Cr |
| Insider holding | 41.36% |
| Dividend yield | 3.65% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Sundrug Co.,Ltd.'s PosiPenta score?
Sundrug Co.,Ltd.'s PosiPenta is 60.60 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Where does Sundrug Co.,Ltd. stand on the Penta Grid?
On the Penta Grid this week, Sundrug Co.,Ltd. is Grid #20 of 140 in the Healthcare sector in Japan, and Grid #346 of 1,958 in Japan.
Which PosiPenta pillar is strongest for Sundrug Co.,Ltd.?
Anchor (stability and dividends), with a score of 79 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Sundrug Co.,Ltd.?
Nitro (momentum), with a score of 38 out of 100: weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.